ClinVar Miner

Submissions for variant NM_003000.2(SDHB):c.286+2T>A (rs587781270)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000128905 SCV000172772 pathogenic Hereditary cancer-predisposing syndrome 2016-11-23 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: Detected in individual satisfying established diagnostic critera for classic disease without a clear mutation,Alterations at the canonical donor/acceptor sites (+/- 1, 2) without other strong (b-level) evidence supporting pathogenicity,In silico models in agreement (deleterious) and/or completely conserved position in appropriate species
Invitae RCV000475161 SCV000554021 pathogenic Gastrointestinal stroma tumor; Paragangliomas 4; Pheochromocytoma 2018-04-08 criteria provided, single submitter clinical testing This sequence change affects a donor splice site in intron 3 of the SDHB gene. It is expected to disrupt mRNA splicing and likely results in an absent or disrupted protein product. Donor and acceptor splice site variants are typically truncating (PMID: 16199547), and truncating variants in SDHB are known to be pathogenic (PMID: 19802898, 19454582). This variant has been reported in an individual affected with malignant paraganglioma (PMID: 16912137), and an individual with renal cell carcinoma (PMID: 23083876). ClinVar contains an entry for this variant (Variation ID: 140773). For these reasons, this variant has been classified as Pathogenic.
GeneDx RCV000481752 SCV000567709 pathogenic not provided 2015-08-19 criteria provided, single submitter clinical testing The c.286+2 T>A variant in the SDHB gene has previously been reported in association with paraganglioma and renal cell cancer (Brouwers et al., 2006; Ghayee et al., 2009; Ricketts et al., 2012). It was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. This variant destroys the canonical splice donor site in intron 3, and is expected to cause abnormal gene splicing. Therefore, the c.286+2 T>A variant is considered pathogenic.
Center for Human Genetics, Inc RCV000660254 SCV000782273 pathogenic Paragangliomas 4 2016-11-01 criteria provided, single submitter clinical testing
Section on Medical Neuroendocrinolgy,National Institutes of Health RCV000505293 SCV000599492 likely pathogenic Hereditary Paraganglioma-Pheochromocytoma Syndromes no assertion criteria provided research

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.